{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:53:45Z","timestamp":1791068025707,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"DOI":"10.1007\/s15010-026-02980-y","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:07:44Z","timestamp":1791018464000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bacteriophage therapy for multidrug- and extensively drug-resistant Acinetobacter baumannii: isolation, characterization, and therapeutic applications"],"prefix":"10.1007","author":[{"given":"Hafiz Anas","family":"Saeed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arslan Ullah","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnoor","family":"Jan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umer","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Usama","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabia","family":"Arooj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz Muhammad Husnain","family":"Azam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazim","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"issue":"1","key":"2980_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12941-020-00349-1","volume":"19","author":"N Karah","year":"2020","unstructured":"Karah N, Haldorsen B, Hegstad K, Simonsen GS, Sundsfjord A, Samuelsen \u00d8. Molecular epidemiology and antimicrobial resistance features of Acinetobacter baumannii clinical isolates from Pakistan. Ann Clin Microbiol Antimicrob. 2020;19(1):2. https:\/\/doi.org\/10.1186\/s12941-020-00349-1.","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"1","key":"2980_CR2","doi-asserted-by":"publisher","first-page":"2289769","DOI":"10.1080\/21505594.2023.2289769","volume":"15","author":"M Lucidi","year":"2024","unstructured":"Lucidi M, Runci F, Pallecchi L, Rossolini GM, Visaggio D, Visca P. Pathogenicity and virulence of Acinetobacter baumannii: factors contributing to the fitness in healthcare settings and the infected host. Virulence. 2024;15(1):2289769. https:\/\/doi.org\/10.1080\/21505594.2023.2289769.","journal-title":"Virulence"},{"issue":"1","key":"2980_CR3","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s12866-025-04012-5","volume":"25","author":"MA Hossain","year":"2025","unstructured":"Hossain MA, Rahman M, Sultana S, et al. Isolation and characterization of Acinetobacter baumannii from environmental waters in Dhaka City, Bangladesh. BMC Microbiol. 2025;25(1):314. https:\/\/doi.org\/10.1186\/s12866-025-04012-5.","journal-title":"BMC Microbiol"},{"issue":"5","key":"2980_CR4","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.12669\/pjms.295.3568","volume":"29","author":"S Begum","year":"2013","unstructured":"Begum S, Hasan F, Hussain S, Shah AA. Prevalence of multi drug resistant Acinetobacter baumannii in the clinical samples from Tertiary Care Hospital in Islamabad, Pakistan. Pak J Med Sci. 2013;29(5):1253\u20138. https:\/\/doi.org\/10.12669\/pjms.295.3568.","journal-title":"Pak J Med Sci"},{"issue":"5","key":"2980_CR5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3390\/antibiotics14050490","volume":"14","author":"F Foglia","year":"2025","unstructured":"Foglia F, D\u2019Agostino M, D\u2019Alonzo F, et al. Prevalence of Acinetobacter baumannii multidrug resistance in university hospital environment. Antibiot (Basel). 2025;14(5):490. https:\/\/doi.org\/10.3390\/antibiotics14050490.","journal-title":"Antibiot (Basel)"},{"issue":"1","key":"2980_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.55519\/JAMC-01-9512","volume":"34","author":"F Jabeen","year":"2022","unstructured":"Jabeen F, Aftab H, Ali A, et al. Antibiotic resistance pattern of Acinetobacter baumannii isolated from bacteremia patients in Pakistan. J Ayub Med Coll Abbottabad. 2022;34(1):95\u2013100. https:\/\/doi.org\/10.55519\/JAMC-01-9512.","journal-title":"J Ayub Med Coll Abbottabad"},{"issue":"1","key":"2980_CR7","first-page":"26","volume":"7","author":"W Farooq","year":"2021","unstructured":"Farooq W, Qadir A, Ahmed S, et al. Molecular characterization of Acinetobacter baumannii isolated from MDR-TB patients of Northern Punjab, Pakistan. Biomed Lett. 2021;7(1):26\u201331.","journal-title":"Biomed Lett"},{"key":"2980_CR8","doi-asserted-by":"publisher","first-page":"1778984","DOI":"10.3389\/fmicb.2026.1778984","volume":"17","author":"JAG Fortaleza","year":"2026","unstructured":"Fortaleza JAG, Pimenta FC, de Oliveira BEM, et al. Bacteriophages targeting Acinetobacter baumannii in the era of antibiotic failure: a review. Front Microbiol. 2026;17:1778984. https:\/\/doi.org\/10.3389\/fmicb.2026.1778984.","journal-title":"Front Microbiol"},{"issue":"3","key":"2980_CR9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.35845\/kmuj.2025.23780","volume":"17","author":"MMUD Malik","year":"2025","unstructured":"Malik MMUD. Bacteriophages: a new weapon against antibiotic resistance. Khyber Med Univ J. 2025;17(3):374\u20136. https:\/\/doi.org\/10.35845\/kmuj.2025.23780.","journal-title":"Khyber Med Univ J"},{"issue":"4","key":"2980_CR10","doi-asserted-by":"publisher","first-page":"dlaf134","DOI":"10.1093\/jacamr\/dlaf134","volume":"7","author":"A Boutzoukas","year":"2025","unstructured":"Boutzoukas A, Doi Y. The global epidemiology of carbapenem-resistant Acinetobacter baumannii. JAC Antimicrob Resist. 2025;7(4):dlaf134. https:\/\/doi.org\/10.1093\/jacamr\/dlaf134.","journal-title":"JAC Antimicrob Resist"},{"issue":"11","key":"2980_CR11","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.12669\/pjms.40.11.10039","volume":"40","author":"A Mumtaz","year":"2024","unstructured":"Mumtaz A, Ali S, Khan M, et al. Investigation of antibiotic resistance and biofilm formation ability of Acinetobacter baumannii isolated from urinary catheters. Pak J Med Sci. 2024;40(11):2643\u20139. https:\/\/doi.org\/10.12669\/pjms.40.11.10039.","journal-title":"Pak J Med Sci"},{"issue":"6","key":"2980_CR12","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3390\/vaccines9060570","volume":"9","author":"C Ma","year":"2021","unstructured":"Ma C, McClean S. Mapping global prevalence of Acinetobacter baumannii and recent vaccine development to tackle it. Vaccines (Basel). 2021;9(6):570. https:\/\/doi.org\/10.3390\/vaccines9060570.","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"2980_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.37962\/jbas.v10i1.146","volume":"10","author":"Q Ul Ain","year":"2019","unstructured":"Ul Ain Q, Naim A, Saeed A. Prevalence and resistance profile of clinical isolates of Acinetobacter species from Karachi, Pakistan. RADS J Biol Res Appl Sci. 2019;10(1):6\u201313. https:\/\/doi.org\/10.37962\/jbas.v10i1.146.","journal-title":"RADS J Biol Res Appl Sci"},{"issue":"3","key":"2980_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/antibiotics9030119","volume":"9","author":"C Ayoub Moubareck","year":"2020","unstructured":"Ayoub Moubareck C, Hammoudi Halat D. Insights into Acinetobacter baumannii: a review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiot (Basel). 2020;9(3):119. https:\/\/doi.org\/10.3390\/antibiotics9030119.","journal-title":"Antibiot (Basel)"},{"issue":"3","key":"2980_CR15","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1128\/CMR.00058-07","volume":"21","author":"AY Peleg","year":"2008","unstructured":"Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538\u201382. https:\/\/doi.org\/10.1128\/CMR.00058-07.","journal-title":"Clin Microbiol Rev"},{"key":"2980_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2147\/IDR.S454321","volume":"17","author":"A Zulfiqar","year":"2024","unstructured":"Zulfiqar A. Investigations on Acinetophage, QAB 3.4, targeting extensively drug-resistant Acinetobacter baumannii isolates. Infect Drug Resist. 2024;17:423\u201334. https:\/\/doi.org\/10.2147\/IDR.S454321.","journal-title":"Infect Drug Resist"},{"key":"2980_CR17","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2147\/IDR.S238666","volume":"13","author":"SN Abdi","year":"2020","unstructured":"Abdi SN, Ghotaslou R, Asgharzadeh M, et al. Acinetobacter baumannii efflux pumps and antibiotic resistance. Infect Drug Resist. 2020;13:423\u201334. https:\/\/doi.org\/10.2147\/IDR.S238666.","journal-title":"Infect Drug Resist"},{"key":"2980_CR18","doi-asserted-by":"publisher","first-page":"107605","DOI":"10.1016\/j.micpath.2025.107605","volume":"204","author":"R Sharma","year":"2025","unstructured":"Sharma R, Lakhanpal D. Acinetobacter baumannii: a comprehensive review of global epidemiology, clinical implications, host interactions, mechanisms of antimicrobial resistance and mitigation strategies. Microb Pathog. 2025;204:107605. https:\/\/doi.org\/10.1016\/j.micpath.2025.107605.","journal-title":"Microb Pathog"},{"key":"2980_CR19","doi-asserted-by":"publisher","first-page":"1565965","DOI":"10.3389\/fmicb.2025.1565965","volume":"16","author":"A Yehya","year":"2025","unstructured":"Yehya A, Al-Marzooq F, Mousa HA, et al. The intricacies of Acinetobacter baumannii: a multifaceted comprehensive review of a multidrug-resistant pathogen and its clinical significance and implications. Front Microbiol. 2025;16:1565965. https:\/\/doi.org\/10.3389\/fmicb.2025.1565965.","journal-title":"Front Microbiol"},{"issue":"11","key":"2980_CR20","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1111\/jcpt.13780","volume":"47","author":"R Dehbanipour","year":"2022","unstructured":"Dehbanipour R, Ghalavand Z. Acinetobacter baumannii: pathogenesis, virulence factors, novel therapeutic options and mechanisms of resistance to antimicrobial agents with emphasis on tigecycline. J Clin Pharm Ther. 2022;47(11):1875\u201384. https:\/\/doi.org\/10.1111\/jcpt.13780.","journal-title":"J Clin Pharm Ther"},{"issue":"12","key":"2980_CR21","doi-asserted-by":"publisher","first-page":"e00707","DOI":"10.1128\/spectrum.00707-25","volume":"13","author":"A Shaikh","year":"2025","unstructured":"Shaikh A, Marathe A, Prajapati B. Genomic analysis of virulence factors of nosocomial MDR A. baumannii from a tertiary care hospital. Microbiol Spectr. 2025;13(12):e00707\u201325. https:\/\/doi.org\/10.1128\/spectrum.00707-25.","journal-title":"Microbiol Spectr"},{"key":"2980_CR22","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.2147\/IDR.S332051","volume":"14","author":"A Gedefie","year":"2021","unstructured":"Gedefie A, Demsis W, Ashagrie M, et al. Acinetobacter baumannii biofilm formation and its role in disease pathogenesis: a review. Infect Drug Resist. 2021;14:3711\u20139. https:\/\/doi.org\/10.2147\/IDR.S332051.","journal-title":"Infect Drug Resist"},{"key":"2980_CR23","doi-asserted-by":"publisher","first-page":"100131","DOI":"10.1016\/j.crmicr.2022.100131","volume":"3","author":"K Upmanyu","year":"2022","unstructured":"Upmanyu K, Haq QMR, Singh R. Factors mediating Acinetobacter baumannii biofilm formation: opportunities for developing therapeutics. Curr Res Microb Sci. 2022;3:100131. https:\/\/doi.org\/10.1016\/j.crmicr.2022.100131.","journal-title":"Curr Res Microb Sci"},{"key":"2980_CR24","doi-asserted-by":"publisher","first-page":"1715193","DOI":"10.3389\/fcimb.2025.1715193","volume":"15","author":"TL Garomsa","year":"2025","unstructured":"Garomsa TL, Shenkutie AM, Leung PHM. Recent advances in host models in studying virulence factors and pathogenesis of Acinetobacter baumannii. Front Cell Infect Microbiol. 2025;15:1715193. https:\/\/doi.org\/10.3389\/fcimb.2025.1715193.","journal-title":"Front Cell Infect Microbiol"},{"issue":"11","key":"2980_CR25","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.molmed.2025.07.004","volume":"31","author":"BA Berryhill","year":"2025","unstructured":"Berryhill BA, Huseby DL, McCall IC, et al. The future of phage therapy in the USA. Trends Mol Med. 2025;31(11):982\u201391. https:\/\/doi.org\/10.1016\/j.molmed.2025.07.004.","journal-title":"Trends Mol Med"},{"issue":"1","key":"2980_CR26","doi-asserted-by":"publisher","first-page":"e0082421","DOI":"10.1128\/AAC.00824-21","volume":"66","author":"S Rao","year":"2022","unstructured":"Rao S, Betancourt-Garcia M, Koka R, et al. Critically ill patient with multidrug-resistant Acinetobacter baumannii respiratory infection successfully treated with intravenous and nebulized bacteriophage therapy. Antimicrob Agents Chemother. 2022;66(1):e0082421. https:\/\/doi.org\/10.1128\/AAC.00824-21.","journal-title":"Antimicrob Agents Chemother"},{"key":"2980_CR27","doi-asserted-by":"publisher","first-page":"1715193","DOI":"10.3389\/fcimb.2025.1715193","volume":"15","author":"TL Garomsa","year":"2025","unstructured":"Garomsa TL, Shenkutie AM, Leung PHM. Recent advances in host models in studying virulence factors and pathogenesis of Acinetobacter baumannii. Front Cell Infect Microbiol. 2025;15:1715193.","journal-title":"Front Cell Infect Microbiol"},{"issue":"7995","key":"2980_CR28","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41586-023-06873-0","volume":"625","author":"C Zampaloni","year":"2024","unstructured":"Zampaloni C, Mattei P, Bleicher K, et al. A novel antibiotic class targeting the lipopolysaccharide transporter. Nature. 2024;625(7995):566\u201371. https:\/\/doi.org\/10.1038\/s41586-023-06873-0.","journal-title":"Nature"},{"issue":"3","key":"2980_CR29","doi-asserted-by":"publisher","first-page":"e0197521","DOI":"10.1128\/AAC.01975-21","volume":"66","author":"HJ Appaneal","year":"2022","unstructured":"Appaneal HJ, Lopes VV, LaPlante KL, Caffrey AR. Treatment, clinical outcomes, and predictors of mortality among a national cohort of admitted patients with Acinetobacter baumannii infection. Antimicrob Agents Chemother. 2022;66(3):e0197521. https:\/\/doi.org\/10.1128\/AAC.01975-21.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2980_CR30","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/antibiotics13030238","volume":"13","author":"P Rafailidis","year":"2024","unstructured":"Rafailidis P, Panagiotidis G, Mavrommatis E, et al. Current therapeutic approaches for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii infections. Antibiot (Basel). 2024;13(3):238. https:\/\/doi.org\/10.3390\/antibiotics13030238.","journal-title":"Antibiot (Basel)"},{"key":"2980_CR31","volume-title":"WHO Bacterial Priority Pathogens List 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development, and Strategies to Prevent and Control Antimicrobial Resistance","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. WHO Bacterial Priority Pathogens List 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development, and Strategies to Prevent and Control Antimicrobial Resistance. Geneva: WHO; 2024."},{"key":"2980_CR32","doi-asserted-by":"publisher","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis. 2024;ciae403. https:\/\/doi.org\/10.1093\/cid\/ciae403.","DOI":"10.1093\/cid\/ciae403"},{"issue":"4","key":"2980_CR33","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli. Clin Microbiol Infect. 2022;28(4):521\u201347. https:\/\/doi.org\/10.1016\/j.cmi.2021.11.025.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"2980_CR34","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","volume":"23","author":"KS Kaye","year":"2023","unstructured":"Kaye KS, Shorr AF, Wunderink RG, et al. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex (ATTACK): a multicentre, randomised, active-controlled, phase 3, non-inferiority trial. Lancet Infect Dis. 2023;23(9):1072\u201384. https:\/\/doi.org\/10.1016\/S1473-3099(23)00184-6.","journal-title":"Lancet Infect Dis"},{"key":"2980_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s00203-026-04785-x","author":"R Ibrahim","year":"2026","unstructured":"Ibrahim R, Aranjani JM. Bacterial defense mechanisms against bacteriophages: an evolutionary arms race. Arch Microbiol. 2026. https:\/\/doi.org\/10.1007\/s00203-026-04785-x.","journal-title":"Arch Microbiol"},{"issue":"11","key":"2980_CR36","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.3390\/antibiotics14111182","volume":"14","author":"Y Wang","year":"2025","unstructured":"Wang Y, Li X, Zhang J, et al. Phage therapy for Acinetobacter baumannii infections: a review on advances in classification, applications, and translational roadblocks. Antibiot (Basel). 2025;14(11):1182. https:\/\/doi.org\/10.3390\/antibiotics14111182.","journal-title":"Antibiot (Basel)"},{"key":"2980_CR37","doi-asserted-by":"publisher","first-page":"1778984","DOI":"10.3389\/fmicb.2026.1778984","volume":"17","author":"JAG Fortaleza","year":"2026","unstructured":"Fortaleza JAG, et al. Bacteriophages targeting Acinetobacter baumannii in the era of antibiotic failure: a review. Front Microbiol. 2026;17:1778984.","journal-title":"Front Microbiol"},{"issue":"14","key":"2980_CR38","doi-asserted-by":"publisher","first-page":"e34849","DOI":"10.1016\/j.heliyon.2024.e34849","volume":"10","author":"Z Guo","year":"2024","unstructured":"Guo Z, Yuan M, Chai J. Mini review advantages and limitations of lytic phages compared with chemical antibiotics to combat bacterial infections. Heliyon. 2024;10(14):e34849. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34849.","journal-title":"Heliyon"},{"issue":"1","key":"2980_CR39","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/1574-6968.12402","volume":"353","author":"ZJ Storms","year":"2014","unstructured":"Storms ZJ, Brown T, Cooper DG, et al. Impact of the cell life-cycle on bacteriophage T4 infection. FEMS Microbiol Lett. 2014;353(1):63\u20138. https:\/\/doi.org\/10.1111\/1574-6968.12402.","journal-title":"FEMS Microbiol Lett"},{"key":"2980_CR40","doi-asserted-by":"publisher","first-page":"1659093","DOI":"10.3389\/fmicb.2025.1659093","volume":"16","author":"V Panteleev","year":"2025","unstructured":"Panteleev V, Kulbachinskiy A, Gelfenbein D. Evaluating phage lytic activity: from plaque assays to single-cell technologies. Front Microbiol. 2025;16:1659093. https:\/\/doi.org\/10.3389\/fmicb.2025.1659093.","journal-title":"Front Microbiol"},{"issue":"7","key":"2980_CR41","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3390\/antibiotics13070609","volume":"13","author":"YJ Choi","year":"2024","unstructured":"Choi YJ, Lee YJ, Park JH, et al. Synergistic antimicrobial effects of phage vB_AbaSi_W9 and antibiotics against Acinetobacter baumannii infection. Antibiot (Basel). 2024;13(7):609. https:\/\/doi.org\/10.3390\/antibiotics13070609.","journal-title":"Antibiot (Basel)"},{"issue":"1","key":"2980_CR42","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1007\/s11033-024-09929-8","volume":"51","author":"S Teymouri","year":"2024","unstructured":"Teymouri S, Pourhajibagher M, Bahador A. A review of the fighting Acinetobacter baumannii on three fronts: antibiotics, phages, and nanoparticles. Mol Biol Rep. 2024;51(1):1044. https:\/\/doi.org\/10.1007\/s11033-024-09929-8.","journal-title":"Mol Biol Rep"},{"issue":"9","key":"2980_CR43","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3390\/antibiotics13090876","volume":"13","author":"L Cui","year":"2024","unstructured":"Cui L, Yang Y, Li J, et al. A comprehensive review on phage therapy and phage-based drug development. Antibiot (Basel). 2024;13(9):876. https:\/\/doi.org\/10.3390\/antibiotics13090876.","journal-title":"Antibiot (Basel)"},{"key":"2980_CR44","doi-asserted-by":"publisher","first-page":"100050","DOI":"10.1016\/j.crmicr.2021.100050","volume":"2","author":"S Makky","year":"2021","unstructured":"Makky S, Dawoud A, Safwat A, et al. The bacteriophage decides own tracks: when they are with or against the bacteria. Curr Res Microb Sci. 2021;2:100050. https:\/\/doi.org\/10.1016\/j.crmicr.2021.100050.","journal-title":"Curr Res Microb Sci"},{"issue":"9","key":"2980_CR45","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1080\/13543784.2025.2552846","volume":"34","author":"DS Kontogiannis","year":"2025","unstructured":"Kontogiannis DS, Romanos LT, Tzvetanova ID, Voulgaris GL, Falagas ME. Antibiotics and non-traditional antimicrobial agents for carbapenem-resistant Acinetobacter baumannii in Phase 1, 2, and 3 clinical trials. Expert Opin Investig Drugs. 2025;34(9):705\u201316. https:\/\/doi.org\/10.1080\/13543784.2025.2552846.","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"2980_CR46","doi-asserted-by":"publisher","first-page":"319","DOI":"10.18502\/ijm.v14i3.9756","volume":"14","author":"S Farajnia","year":"2022","unstructured":"Farajnia S, Lotfi M, Tanomand A, et al. The molecular characterization of colistin-resistant isolates of Acinetobacter baumannii from patients at intensive care units. Iran J Microbiol. 2022;14(3):319\u201327. https:\/\/doi.org\/10.18502\/ijm.v14i3.9756.","journal-title":"Iran J Microbiol"},{"issue":"5","key":"2980_CR47","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4103\/1735-5362.213985","volume":"12","author":"H Ghajavand","year":"2017","unstructured":"Ghajavand H, Esfahani BN, Mohammadi M, et al. Isolation of bacteriophages against multidrug resistant Acinetobacter baumannii. Res Pharm Sci. 2017;12(5):373\u201380. https:\/\/doi.org\/10.4103\/1735-5362.213985.","journal-title":"Res Pharm Sci"},{"issue":"1","key":"2980_CR48","doi-asserted-by":"publisher","first-page":"43520","DOI":"10.1038\/s41598-025-28332-4","volume":"15","author":"X Chen","year":"2025","unstructured":"Chen X, Liu Y, Wang H, et al. Isolation and characterization of two novel phages with lytic activity against multidrug-resistant Acinetobacter baumannii strains: potential for phage therapy. Sci Rep. 2025;15(1):43520. https:\/\/doi.org\/10.1038\/s41598-025-28332-4.","journal-title":"Sci Rep"},{"issue":"1","key":"2980_CR49","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1186\/s12879-023-08794-9","volume":"23","author":"T Hailemichael","year":"2023","unstructured":"Hailemichael T, Abebe T, Gebre-Selassie S, et al. Isolation of virulent phages against multidrug-resistant Acinetobacter baumannii recovered from inanimate objects of Jimma Medical Center, Southwest Ethiopia. BMC Infect Dis. 2023;23(1):820. https:\/\/doi.org\/10.1186\/s12879-023-08794-9.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"2980_CR50","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3390\/v12060610","volume":"12","author":"S Badawy","year":"2020","unstructured":"Badawy S, Nour M, Shata S, et al. Identification and functional analysis of temperate Siphoviridae bacteriophages of Acinetobacter baumannii. Viruses. 2020;12(6):610. https:\/\/doi.org\/10.3390\/v12060610.","journal-title":"Viruses"},{"issue":"3","key":"2980_CR51","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/1758-2229.13053","volume":"14","author":"S Rai","year":"2022","unstructured":"Rai S, Kumar A. Bacteriophage therapeutics to confront multidrug-resistant Acinetobacter baumannii \u2013 a global health menace. Environ Microbiol Rep. 2022;14(3):347\u201364. https:\/\/doi.org\/10.1111\/1758-2229.13053.","journal-title":"Environ Microbiol Rep"},{"issue":"9","key":"2980_CR52","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.22038\/ijbms.2021.56596.12677","volume":"24","author":"L Rahimzadeh Torabi","year":"2021","unstructured":"Rahimzadeh Torabi L, Moghaddam MM, Hosseini SN, et al. Isolation, characterization, and effectiveness of bacteriophage P\u0278-Bw-Ab against XDR Acinetobacter baumannii isolated from nosocomial burn wound infection. Iran J Basic Med Sci. 2021;24(9):1254\u201363. https:\/\/doi.org\/10.22038\/ijbms.2021.56596.12677.","journal-title":"Iran J Basic Med Sci"},{"issue":"1","key":"2980_CR53","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12866-019-1443-5","volume":"19","author":"J Jeon","year":"2019","unstructured":"Jeon J, Park JH, Yong D. Efficacy of bacteriophage treatment against carbapenem-resistant Acinetobacter baumannii in Galleria mellonella larvae and a mouse model of acute pneumonia. BMC Microbiol. 2019;19(1):70. https:\/\/doi.org\/10.1186\/s12866-019-1443-5.","journal-title":"BMC Microbiol"},{"key":"2980_CR54","doi-asserted-by":"publisher","first-page":"863129","DOI":"10.3389\/fmicb.2022.863129","volume":"13","author":"M Lowe","year":"2022","unstructured":"Lowe M, Ehlers MM, Ismail F, et al. Molecular characterisation of Acinetobacter baumannii isolates from bloodstream infections in a tertiary-level hospital in South Africa. Front Microbiol. 2022;13:863129. https:\/\/doi.org\/10.3389\/fmicb.2022.863129.","journal-title":"Front Microbiol"},{"issue":"5","key":"2980_CR55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.21315\/mjms2023.30.5.2","volume":"30","author":"F Raees","year":"2023","unstructured":"Raees F, Khan AU, Khan AA, et al. Potential usefulness of bacteriophages for the treatment of multidrug-resistant Acinetobacter infection. Malays J Med Sci. 2023;30(5):7\u201322. https:\/\/doi.org\/10.21315\/mjms2023.30.5.2.","journal-title":"Malays J Med Sci"},{"issue":"4","key":"2980_CR56","doi-asserted-by":"publisher","first-page":"e0034123","DOI":"10.1128\/spectrum.00341-23","volume":"11","author":"J Luo","year":"2023","unstructured":"Luo J, Xie L, Li Y, et al. Synergistic antibacterial effect of phage pB3074 in combination with antibiotics targeting cell wall against multidrug-resistant Acinetobacter baumannii in vitro and ex vivo. Microbiol Spectr. 2023;11(4):e0034123. https:\/\/doi.org\/10.1128\/spectrum.00341-23.","journal-title":"Microbiol Spectr"},{"issue":"4","key":"2980_CR57","doi-asserted-by":"publisher","first-page":"e0009622","DOI":"10.1128\/spectrum.00096-22","volume":"10","author":"J Luo","year":"2022","unstructured":"Luo J, Xie L, Yang M, et al. Bactericidal synergism between phage YC#06 and antibiotics: a combination strategy to target multidrug-resistant Acinetobacter baumannii in vitro and in vivo. Microbiol Spectr. 2022;10(4):e0009622. https:\/\/doi.org\/10.1128\/spectrum.00096-22.","journal-title":"Microbiol Spectr"},{"issue":"10","key":"2980_CR58","doi-asserted-by":"publisher","first-page":"e0085525","DOI":"10.1128\/spectrum.00855-25","volume":"13","author":"YJ Choi","year":"2025","unstructured":"Choi YJ, Lee YJ, Lee DS, et al. Overcoming phage resistance: efficacy of sequential phage-colistin therapy against carbapenem-resistant Acinetobacter baumannii. Microbiol Spectr. 2025;13(10):e0085525. https:\/\/doi.org\/10.1128\/spectrum.00855-25.","journal-title":"Microbiol Spectr"},{"issue":"1","key":"2980_CR59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/antibiotics15010017","volume":"15","author":"IA Stoian","year":"2025","unstructured":"Stoian IA, Popa M, Gheorghe-Barbu I, et al. Multidrug-resistant Acinetobacter baumannii: resistance mechanisms, emerging therapies, and prevention\u2014a narrative review. Antibiot (Basel). 2025;15(1):17. https:\/\/doi.org\/10.3390\/antibiotics15010017.","journal-title":"Antibiot (Basel)"},{"issue":"7","key":"2980_CR60","doi-asserted-by":"publisher","first-page":"e0046724","DOI":"10.1128\/jvi.00467-24","volume":"98","author":"S Li","year":"2024","unstructured":"Li S, Liu J, Wang L, et al. In vivo efficacy of phage cocktails against carbapenem resistant Acinetobacter baumannii in the rat pneumonia model. J Virol. 2024;98(7):e0046724. https:\/\/doi.org\/10.1128\/jvi.00467-24.","journal-title":"J Virol"},{"issue":"1","key":"2980_CR61","doi-asserted-by":"publisher","first-page":"11578","DOI":"10.1038\/s41598-025-95654-8","volume":"15","author":"AK Orozco-Ochoa","year":"2025","unstructured":"Orozco-Ochoa AK, Salazar D, S\u00e1nchez S, et al. Bacteriophage Indie resensitizes multidrug-resistant Acinetobacter baumannii to antibiotics in vitro. Sci Rep. 2025;15(1):11578. https:\/\/doi.org\/10.1038\/s41598-025-95654-8.","journal-title":"Sci Rep"},{"issue":"4","key":"2980_CR62","doi-asserted-by":"publisher","first-page":"ofy064","DOI":"10.1093\/ofid\/ofy064","volume":"5","author":"S LaVergne","year":"2018","unstructured":"LaVergne S, Hamilton T, Biswas B, et al. Phage therapy for a multidrug-resistant Acinetobacter baumannii craniectomy site infection. Open Forum Infect Dis. 2018;5(4):ofy064. https:\/\/doi.org\/10.1093\/ofid\/ofy064.","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"2980_CR63","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3390\/biology11091338","volume":"11","author":"KG Dolma","year":"2022","unstructured":"Dolma KG, Singh S, Gupta R, et al. Virulence characteristics and emerging therapies for biofilm-forming Acinetobacter baumannii: a review. Biology (Basel). 2022;11(9):1338. https:\/\/doi.org\/10.3390\/biology11091338.","journal-title":"Biology (Basel)"},{"issue":"6","key":"2980_CR64","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3390\/idr16060088","volume":"16","author":"M Palma","year":"2024","unstructured":"Palma M, Qi B. Advancing phage therapy: a comprehensive review of the safety, efficacy, and future prospects for the targeted treatment of bacterial infections. Infect Dis Rep. 2024;16(6):1127\u201381. https:\/\/doi.org\/10.3390\/idr16060088.","journal-title":"Infect Dis Rep"},{"key":"2980_CR65","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-025-04060-2","author":"M F\u00fcrst-Wilmes","year":"2025","unstructured":"F\u00fcrst-Wilmes M, Respondek V, Lilienthal N, Buss K, D\u00fcchting A. Regulation of phage therapy medicinal products: developments, challenges and opportunities. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2025. https:\/\/doi.org\/10.1007\/s00103-025-04060-2.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"1","key":"2980_CR66","doi-asserted-by":"publisher","first-page":"24404","DOI":"10.1038\/s41598-024-74841-z","volume":"14","author":"L Cui","year":"2024","unstructured":"Cui L, Yang Y, Li J, et al. Current and future directions in bacteriophage research for developing therapeutic innovations. Sci Rep. 2024;14(1):24404. https:\/\/doi.org\/10.1038\/s41598-024-74841-z.","journal-title":"Sci Rep"},{"key":"2980_CR67","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.3389\/fmicb.2017.02659","volume":"8","author":"Y Hua","year":"2017","unstructured":"Hua Y, Luo T, Yang Y, et al. Phage therapy as a promising new treatment for lung infection caused by carbapenem-resistant Acinetobacter baumannii in mice. Front Microbiol. 2017;8:2659. https:\/\/doi.org\/10.3389\/fmicb.2017.02659.","journal-title":"Front Microbiol"},{"key":"2980_CR68","doi-asserted-by":"publisher","first-page":"105942","DOI":"10.1016\/j.ebiom.2025.105942","volume":"120","author":"Z Liu","year":"2025","unstructured":"Liu Z, Wang Y, Zhang L, et al. Efficacy of precisely tailored phage cocktails targeting carbapenem-resistant Acinetobacter baumannii reveals evolutionary trade-offs: a proof-of-concept study. EBioMedicine. 2025;120:105942. https:\/\/doi.org\/10.1016\/j.ebiom.2025.105942.","journal-title":"EBioMedicine"},{"issue":"1","key":"2980_CR69","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13756-021-00931-w","volume":"10","author":"K Iskandar","year":"2021","unstructured":"Iskandar K, Molinier L, Hallit S, et al. Surveillance of antimicrobial resistance in low- and middle-income countries: a scattered picture. Antimicrob Resist Infect Control. 2021;10(1):63. https:\/\/doi.org\/10.1186\/s13756-021-00931-w.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"7995","key":"2980_CR70","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-023-06799-7","volume":"625","author":"KS Pahil","year":"2024","unstructured":"Pahil KS, Gilman MSA, Bhardwaj V, et al. A new antibiotic traps lipopolysaccharide in its intermembrane transporter. Nature. 2024;625(7995):572\u20137. https:\/\/doi.org\/10.1038\/s41586-023-06799-7.","journal-title":"Nature"},{"key":"2980_CR71","doi-asserted-by":"publisher","first-page":"e02682025","DOI":"10.1590\/0037-8682-0268-2025","volume":"58","author":"PHM Lima","year":"2025","unstructured":"Lima PHM, da Silva RC, de Oliveira AP, et al. Integrative review on Acinetobacter baumannii as a multidrug-resistant pathogen: resistance mechanisms and therapeutic perspectives in the context of nosocomial infections. Rev Soc Bras Med Trop. 2025;58:e02682025. https:\/\/doi.org\/10.1590\/0037-8682-0268-2025.","journal-title":"Rev Soc Bras Med Trop"},{"issue":"8","key":"2980_CR72","doi-asserted-by":"publisher","first-page":"e0106324","DOI":"10.1128\/aac.01063-24","volume":"69","author":"CJ Kubin","year":"2025","unstructured":"Kubin CJ, Garzia C, Uhlemann AC. Acinetobacter baumannii treatment strategies: a review of therapeutic challenges and considerations. Antimicrob Agents Chemother. 2025;69(8):e0106324. https:\/\/doi.org\/10.1128\/aac.01063-24.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2980_CR73","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1128\/AAC.02972-15","volume":"60","author":"M Thandar","year":"2016","unstructured":"Thandar M, Lood R, Winer BY, Deutsch DR, Euler CW, Fischetti VA. Novel engineered peptides of a phage lysin as effective antimicrobials against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60(5):2671\u20139. https:\/\/doi.org\/10.1128\/AAC.02972-15.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2980_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ddc4010001","volume":"4","author":"S Morales","year":"2025","unstructured":"Morales S, Hyman P. Quis custodiet? Are regulations slowing phage therapy? Drugs Drug Candidates. 2025;4(1):1. https:\/\/doi.org\/10.3390\/ddc4010001.","journal-title":"Drugs Drug Candidates"},{"issue":"12","key":"2980_CR75","doi-asserted-by":"publisher","first-page":"114026","DOI":"10.1016\/j.isci.2025.114026","volume":"28","author":"PO Kenney","year":"2025","unstructured":"Kenney PO, Hingst JR, Smith LM, et al. A bacteriophage genus infects carbapenem resistant Acinetobacter baumannii via a non-capsular receptor and provides protection in vivo. iScience. 2025;28(12):114026. https:\/\/doi.org\/10.1016\/j.isci.2025.114026.","journal-title":"iScience"},{"key":"2980_CR76","doi-asserted-by":"publisher","first-page":"1716306","DOI":"10.3389\/fmed.2025.1716306","volume":"12","author":"J Lin","year":"2025","unstructured":"Lin J, Chen Y, Liu Z, et al. Case report: bacteriophage-antibiotic therapy for extensively drug-resistant Acinetobacter baumannii in critically ill patient with respiratory infection. Front Med (Lausanne). 2025;12:1716306. https:\/\/doi.org\/10.3389\/fmed.2025.1716306.","journal-title":"Front Med (Lausanne)"},{"key":"2980_CR77","doi-asserted-by":"publisher","first-page":"ftae012","DOI":"10.1093\/femspd\/ftae012","volume":"82","author":"S Rastegar","year":"2024","unstructured":"Rastegar S, Skurnik M, Tadjrobehkar O, et al. Characterization of bacteriophage vB_AbaS_SA1 and its synergistic effects with antibiotics against clinical multidrug-resistant Acinetobacter baumannii isolates. Pathog Dis. 2024;82:ftae012. https:\/\/doi.org\/10.1093\/femspd\/ftae012.","journal-title":"Pathog Dis"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02980-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02980-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02980-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:02:25Z","timestamp":1791064945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02980-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":77,"alternative-id":["2980"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02980-y","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"30 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests. No financial or non-financial conflicts of interest exist that could inappropriately influence this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This is a review article that does not involve human subjects, animals, or human data requiring ethical approval.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data or identifiable information.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}